Temozolomide: a novel oral alkylating agent

References

• Coleman MP, Babb P, Damiecki P et al Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS region. Studies in medical and population subjects no. 61. The Stationary Office, London, UK, 331–342 (1999).
   Google Scholar
• Balch CM, Reintgen DS, Kirkwood JM et al Cutaneous melanoma. In: Cancer: Principles and Practices in Oncology (5th Edition). De Vita VT, Jr. (Ed.), Lippincott, Philadelphia, USA, 1947-1994 (1997).
   Google Scholar
• Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5, 144–151 (2000).
   PubMedGoogle Scholar
• Lee YT Malignant melanoma: patterns of metastasis. Can. J. Physician 30, 137 (1980).
   Google Scholar
• Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomised trial of the Dartmouth regime versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol 17, 2745–2761 (1999).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT Dutcher JP et al High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Clin. Oncol 17, 2105–2116 (1999).
   Google Scholar
• Coleman MP, Babb P, Damiecki P et al Cancer survival trends in England and Wales, 1971–1995: deprivation and NHS region. Studies in medical and population subjects no. 61. The Stationary Office, London, UK, 457–458 (1999).
   Google Scholar
• Bower M, Newlands ES, Bleehan NM et al. Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol 40, 484–488 (1997).
   PubMed Web of Science ®Google Scholar
• Fine H, Dear KBG, Loeffler JS et al Meta-analysis of radiation therapy with or without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585–2597 (1992).
   Google Scholar
• Brada M, Thomas DGT, Bleehan NM et al Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG) BROS. Proc. Am. Soc. Clin. Oncol 17, 1543a (1998).
   Google Scholar
• Newlands ES, Stevens MEG, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer 7i-eat. Rev. 23, 35–61 (1997).
   Google Scholar
• •A straightforward description of the preclinical development of temozolomide and of early clinical data is provided. This also provides a more detailed description of strategies to overcome resistance to the drug.
   Google Scholar
• Stevens ME, Hickman JA, Langdon SP et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoy1-3-methylimidazo [5,1- di- 1, 2, 3,5-tetra-4 (3 H)-one (CCRG 81045; M &B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47, 5846–5852 (1987).
   PubMed Web of Science ®Google Scholar
• Saffhill R, Margison GP, O'Connor PJ. Mechanisms of carcinogenesis induced by alkylating agents. Biochimica Biophysica Acts 823, 111–145 (1985).
   PubMed Web of Science ®Google Scholar
• D'Atri S, Tentori L, Lacal PM et al Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mal Pharmacol 54, 334–341 (1998).
   PubMed Web of Science ®Google Scholar
• Kaina B, Ziouta A, Ochs K, Coquerelle T Chromosomal instability reproductive cell death and apoptosis induced by O-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat. Res. 381, 227–241 (1997).
   PubMed Web of Science ®Google Scholar
• Lee SM, Thatcher N, Crowther D et al. Inactivation of 06-alkyltransferase-DNA alkyltransferase in human peripheral mononuclear cells by temozolomide. BE j Cancer 69, 452–456 (1994).
   Google Scholar
• Middleton MR, Lunn JM, Morris C et al 06-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br. Cancer 78(9), 1199–1202 (1998).
   Google Scholar
• Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. j Clin. Oncol 16, 3851–3857 (1998).
   Google Scholar
• Selzer E, Schlagbauer-Wadl H, Okamato I et al Expression of bc1-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res. 8, 197–203 (1998).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Blackledge GR, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. Cancer 65, 287–291 (1992).
   Google Scholar
• Reidenberg P, Statkevich P, Judson I et al Effect of food on the oral bioavailability of temozolomide, a new chemotherapeutic agent. Proc. Am. Soc. Clin. Pharmacol Ther. 59, 199a (1996).
   Google Scholar
• Baker SD, Wirth M, Statkevich P et al Absorption, metabolism and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 5, 309–317 (1999).
   Google Scholar
• Patel M, McCully C, Godwin K et al Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc. Am. Soc. Clin. Oncol 14, 461a (1995).
   Google Scholar
• Meikle SR, Matthews JC, Brock CS et al Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and position emission tomography: a feasibility study. Cancer Chemother. Pharmacol 42, 183–193 (1998).
   PubMedGoogle Scholar
• Tsang LLH, Farmer PB, Gescher A et al Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother. Pharmacol 26, 429–436 (1990).
   PubMed Web of Science ®Google Scholar
• Brock CS, Newlands ES, Wedge SR et al Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 58, 4363–4367 (1998).
   PubMed Web of Science ®Google Scholar
• Britten CD, Rowinsky EK, Baker SD et al Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin. Cancer Res. 5, 1629–1637 (1999).
   PubMed Web of Science ®Google Scholar
• Azzabi AS, Calvert AH, Verrill M et al I and pharmacokinetic study of temozolomide and paclitaxel in the treatment of malignant melanoma. Clin. Cancer Res. 6(Suppl.), 539a (2000).
   Google Scholar
• Kirkwood JM, Agarwala SS, Diaz B et al I study of temozolomide in combination with interferon a-2b in metastatic malignant melanoma. Proc. Am Soc. Clin. Oncol 16, 491a (1997).
   Google Scholar
• Arance A, Middleton M, Lorigan PC et al -arm Phase II study of temozolomide (TMZ) in metastatic melanoma (MM): preliminary results. Proc. Am. Soc. Clin. Oncol 19, 2257 (2000).
   Google Scholar
• Patel V, Elion G, Houghton P et al -dependent activity of temozolomide plus CPT-11 against a human central nervous system tumour-derived xenograft. Clin. Cancer Res. 6, 4154–4157 (2000).
   Google Scholar
• Bleehan NM, Newlands ES, Lee SM et al Research Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. awl 13(4), 910–913 (1995).
   Google Scholar
• ••Key Phase II trial of temozolomide inmelanoma.
   Google Scholar
• Middleton M, Lee SM, Arance A et al 06- formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a Phase II study. Int. .1. Cancer88, 469–473 (2000).
   Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al Phase II trial of temozolomide patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Clin. Oncol 17, 2762–2771 (1999).
   Google Scholar
• ••Major study leading to the registration oftemozolomide for high-grade glioma.
   Google Scholar
• Stupp R, Ostermann Kraljevic S, Dietrich et al Promising survival with concomitant and adjuvant temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. 0=1 19, 632a (2000).
   Google Scholar
• Woll PJ, Judson I, Lee S et al. in adult patients with advanced soft tissue sarcoma: a Phase II study of the EORTC soft tissue and bone sarcoma group. Eur.j Cancer 35, 410–412 (1999).
   PubMed Web of Science ®Google Scholar
• Woll PJ, Crowther D, Johnson PMW et al. II trial of temozolomide in low-grade non-Hodgkins lymphoma. Br. Cancer72, 183–184 (1995).
   Google Scholar
• Chan A, Thomas T, Kwan W et al Phase II of temodal in the treatment of patients with advanced nasopharyngeal carcinoma. Cancer Chemother. Pharmacol 42, 247–249 (1998).
   PubMed Web of Science ®Google Scholar
• van Brussel J, Busstra M, Lang M et al A II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother. Phalmacol 45, 509–512 (2000).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Feld R, Hedley D et al A Phase study of temozolomide in advanced untreated pancreatic cancer. Invest. New Drugs16(1), 77–79 (1998).
   PubMedGoogle Scholar
• Middleton MR, Grob JJ, Aaronson N et al Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. j Clin. Oncol 18, 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• ••Key Phase III trial of temozolomidecompared with dacarbazine in melanoma.
   Google Scholar
• Yung WK, Levin VA, Albright J et al A II study of temozolomide vs. procarbazine in glioblastoma multiforme at first relapse. Br. Cancer83, 588–593 (2000).
   Google Scholar
• ••Major study leading to the registration oftemozolomide for high-grade glioma.
   Google Scholar
• Summers Y, Middleton MR, Calvert H et Effect of temozolomide (TMZ) on central nervous system (CNS) relapse in patients with advanced melanoma. Proc. Am. Soc. Clin. 0=1 18, 531a (1999).
   Google Scholar
• Jaeckle IKA et al Phase II evaluation of and 13-cis retinoic acid for the treatment of recurrent and progressive malignant gliomas (NABTC 98–03). Proc. Am. Assoc. Clin. Oncol 19, 629a (2000).
   Google Scholar
• Dolan M, Pegg A. 06-benzylguanine and role in chemotherapy. Clin. Cancer Res. (1997) 3, 837–847.
   PubMed Web of Science ®Google Scholar
• •Review of d-benzylguanine development.
   Google Scholar
• Middleton M, Ranson M, Lee S et al Phase study of 4-bromothenylguanine (4-BTG, PaTrin2), an alkyltransferase inactivator and temozolomide. Clin. Cancer Res. 6 (Suppl.), 538a (2000).
   Google Scholar
• Jansen B, Wacheck V, Heere-Ress E et al treatment with bc1-2 antisense down-regulates tumor responses in patients with melanoma when combined with dacarbazine. Am. Assoc. Cancer Res. LB23 (2000).
   Google Scholar
• •A Phase I trial of G3139.
   Google Scholar
• Abrey L, Olson J, Boutros D et al A Phase study of temozolomide for recurrent brain metastases. Proc. Am. Soc. Clin. 0=1 19, 643a (2000).
   Google Scholar
• Christodoulou C, Bafaloukos D, Kosmidis P et al Temozolomide (TMZ) in patients with brain metastases from solid tumours. A Hellenic Cooperative Oncology Group study. Proc. Am. Soc. Clin. 0=1 19, 665a (2000).
   Google Scholar
• Hillner B, Agarwala S, Middleton M. Post economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. j Clin. 0=1 18, 1474–1480 (2000).
   Google Scholar
• •Cost issues arising from [41].
   Google Scholar